Immunome (IMNM) received a worldwide license from Hummingbird Bioscience to monoclonal antibodies for a single undisclosed target, the biotherapeutics company said Tuesday.
Hummingbird said it will receive an upfront payment and is eligible for future development and commercial milestone payments and royalties.
Financial terms were not disclosed.
Immune will carry out research, development, manufacturing and commercialization of products incorporating these antibodies, according to Hummingbird.
Price: 11.12, Change: -0.08, Percent Change: -0.71
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.